in a double-blind cross-over trial in 19 asthmatic patients with reversible airways obstruction , oral administration of both clenbuterol ( 40 microgram ) and salbutamol ( 4 mg ) caused significantly greater increased in peak expiratory flow rate ( pefr ) than placebo , that of clenbuterol lasting longer .
C0004096
asthmatic
C0001927
salbutamol